24 completed, 10 terminated, 9 recruiting, 4 active not recruiting. 50 Phase 2, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 50 | Completed 24, Terminated 10, Recruiting 9, Active not recruiting 4, Withdrawn 2, Unknown 1 |
| Phase 1 | 6 | Completed 4, Terminated 2 |
Follow Vismodegib: new trials by email Literature Review of Vismodegib trials Research Report on Vismodegib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma SP-002, Vismodegib - Basal Cell Carcinoma | Phase 2 | Recruiting | Stamford Pharmaceuticals, Inc. | 80 | 2024-04-09 | 2024-09-20 |
| Radiotherapy by Sonic Hedgehog Pathway Inhibitors in Basal Cell Carcinoma Radiotherapy, Observation, Vismodegib - Basal Cell Carcinoma, Radiotherapy; Complications | Phase 2 | Recruiting | University Hospital, Lille | 82 | 2023-06-20 | 2025-09-30 |
| Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Vismodegib, Atezolizumab - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma | Phase 2 | Recruiting | Ronald Buckanovich | 48 | 2023-05-15 | 2026-06-18 |
| The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs Alectinib, Cobimetinib, Vismodegib - Advanced Cancer, Solid Tumor | Phase 2 | Recruiting | Helsinki University Central Hospital | 250 | 2021-12-10 | 2024-07-15 |
| Improving Public Cancer Care by Implementing Precision Medicine in Norway Atezolizumab - Cancer Metastatic | Phase 2 | Recruiting | Oslo University Hospital | 3000 | 2021-04-01 | 2024-02-29 |
| ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling Alectinib, Atezolizumab, Avelumab - Cancer, Tumors | Phase 2 | Recruiting | Ulrik Lassen | 300 | 2020-08-24 | 2025-07-25 |
| Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome Vismodegib, Nivolumab, Ipilimumab - Basal Cell Nevus Syndrome | Phase 2 | Withdrawn | Columbia University | 2019-07-01 | 2019-12-18 | |
| A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Alectinib, Vismodegib, Ipatasertib - Cancer of Unknown Primary Site | Phase 2 | Completed | Hoffmann-La Roche | 529 | 2018-07-10 | 2025-11-19 |
| NCT Neuro Master Match - N²M² (NOA-20) APG101, Alectinib, Idasanutlin - Glioblastoma, Adult | Phase 1 / Phase 2 | Completed | University Hospital Heidelberg | 228 | 2018-05-07 | 2023-09-28 |
| Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) Olaparib, Dasatinib, Nivolumab plus Ipilimumab - Lymphoma, Non-Hodgkin, Multiple Myeloma | Phase 2 | Recruiting | Canadian Cancer Trials Group | 720 | 2018-03-23 | 2026-03-27 |
| Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell Carcinoma Vismodegib - Basal Cell Carcinoma | Phase 2 | Completed | SRH Wald-Klinikum Gera GmbH | 40 | 2017-01-01 | 2022-02-11 |
| To Assess The Efficacy And Safety Of Vismodegib And Radiotherapy In Advanced Basal Cell Carcinoma Vismodegib, Radiotherapy - Carcinoma, Basal Cell | Phase 2 | Terminated | Istituto Clinico Humanitas | 14 | 2016-10-01 | 2020-01-29 |
| The Drug Rediscovery Protocol (DRUP Trial) Panitumumab, Olaparib, Dabrafenib - Cancer, Tumors | Phase 2 | Recruiting | The Netherlands Cancer Institute | 1550 | 2016-08-01 | 2024-01-24 |
| Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T) Biopsy Procedure, Biospecimen Collection, Echocardiography Test - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 34 | 2016-06-20 | 2026-10-16 |
| Addition of Vismodegib to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients vismodegib, Paclitaxel, Epirubicin - Breast Cancer | Phase 2 | Unknown | Clinica Universidad de Navarra, Universidad de Navarra | 40 | 2016-04-01 | 2017-10-24 |
| Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer Pembrolizumab, Vismodegib - Skin Basal Cell Carcinoma | Phase 1 / Phase 2 | Completed | Anne Chang | 16 | 2016-02-01 | 2019-03-08 |
| A Phase 2, Single-center, Single-arm, Open Label Trial of Vismodegib in Patients With Keratocystic Odontogenic Tumors vismodegib - Keratocystic Odontogenic Tumor | Phase 2 | Completed | NYU College of Dentistry | 2 | 2015-10-27 | 2021-02-18 |
| Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas Vismodegib, FAK Inhibitor GSK2256098, Capivasertib - Intracranial Meningioma, Recurrent Meningioma | Phase 2 | Recruiting | Alliance for Clinical Trials in Oncology | 124 | 2015-09-28 | 2026-10-19 |
| Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease Laboratory Biomarker Analysis, Vismodegib - Chronic Graft Versus Host Disease | Phase 2 | Terminated | National Cancer Institute (NCI) | 6 | 2015-09-08 | 2021-07-19 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Adavosertib, Afatinib, Afatinib Dimaleate - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 6452 | 2015-08-17 | 2026-10-26 |
Showing 20 of 50. Sign in to see all of them.
Carcinoma, Basal Cell (14) · Neoplasms (5) · Medulloblastoma (4) · Multiple Myeloma (3) · Pancreatic Neoplasms (3) · Basal Cell Nevus Syndrome (2) · Brain Neoplasms (2) · Breast Neoplasms (2) · Chondrosarcoma (2) · Colorectal Neoplasms (2) · Glioblastoma (2) · Hematologic Neoplasms (2) · Lymphoma (2) · Ovarian Neoplasms (2) · Prostatic Neoplasms (2)
National Cancer Institute (NCI) (14) · Hoffmann-La Roche (6) · Genentech, Inc. (3) · University Hospital, Lille (2) · Abel Torres, MD (1) · Alliance for Clinical Trials in Oncology (1) · Anne Chang (1) · Canadian Cancer Trials Group (1) · Centre Leon Berard (1) · Clinica Universidad de Navarra, Universidad de Navarra (1) · Columbia University (1) · Giselle Sholler (1) · Helsinki University Central Hospital (1) · Istituto Clinico Humanitas (1) · Lisa Bax (1)
United States (29) · France (8) · Canada (6) · Germany (6) · Italy (5) · Netherlands (4) · Spain (4) · United Kingdom (4) · Australia (3) · Austria (3) · Denmark (3) · Finland (3) · Mexico (3) · Norway (3) · Switzerland (3)
Amar Gajjar (2) · Abel Torres, MD (1) · Albert Cornelius, MD (1) · Amar Gajjar, MD (1) · Anne Lynn S Chang, MD (1) · Anne S Tsao (1) · Antoine Italiano (1) · Armando Santoro, MD (1) · Brian L Schmidt, DDS, MD, PhD (1) · Chandra Belani (1) · Charles Nock, MD (1) · Christopher Logothetis (1) · Clara Curiel-Lewandroski (1) · Daniel J Renouf (1)
PMID 26169613, PMID 20818327, PMID 24170610, PMID 25278454, PMID 25981813, PMID 26527777, PMID 26586415, PMID 28188086, PMID 28325399, PMID 29073584, PMID 29320312, PMID 29777299, PMID 30857956, PMID 32374193, PMID 32463741, PMID 33048619, PMID 33823018, PMID 33997740, PMID 34339623, PMID 34876409, PMID 35086719, PMID 35133871, PMID 35138919, PMID 35568909, PMID 35598186, PMID 35649212, PMID 36288512, PMID 36351402, PMID 36814246, PMID 36870947, PMID 36951168, PMID 37053535, PMID 37165841, PMID 37322121, PMID 37424386, PMID 37793085, PMID 37934000, PMID 38591867, PMID 38630551, PMID 39096924, PMID 39666929, PMID 39693587, PMID 39913886, PMID 40073837, PMID 40865033, PMID 40913172, PMID 41066729, PMID 41545592, PMID 41986720, PMID 42691436
U10CA180820 (3), N01CM00038 (2), N01CM00071 (2), P30CA014599 (2), U01CA081457 (2), 2014 (1), 2015 (1), 2017 (1), N01CM00039 (1), N01CM00070 (1), N01CM62201 (1), N01CM62202 (1), N01CM62204 (1), N01CM62206 (1), N01CM62209 (1)